Clinical trial
Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment…
NCT00025896 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00025896 |
|---|---|
| Title | Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease |
| Official title | A Prospective Multinational, Multicenter, Clinical Trial of the Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase (rhGAA) in Cross-Reacting Immunologic Material-Positive Patients With Classical Infantile Pompe Disease |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pompe Disease, Glycogen Storage Disease Type II, Acid Maltase Deficiency Disease, Glycogenosis 2 |
| Intervention type | Drug |
| Interventions | recombinant human acid alpha-glucosidase (rhGAA) |
| Enrollment | 8 |
| Start date | May 1, 2001 |
| Completion | Sep 1, 2002 |
| First posted | Nov 1, 2001 |
| Last update posted | Nov 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: